Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancerPOAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patientsHelomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options According to the American Cancer Society, an estimated 21,750 women received a new diagnosis of ovarian cancer this year, and almost…